Gland Pharma schedules analyst meeting on June 25, 2026
Gland Pharma has scheduled a one-on-one analyst and institutional investor meeting with Ambit PMS for June 25, 2026, arranged by B&K / 360One. The disclosure was made under SEBI regulations, and the schedule remains subject to change due to exigencies.

*this image is generated using AI for illustrative purposes only.
Gland Pharma has scheduled an analyst and institutional investor meeting for June 25, 2026. The meeting will be a one-on-one session with Ambit PMS, arranged by B&K / 360One. This interaction is part of the company's ongoing engagement with the investment community.
The disclosure was made pursuant to Regulation 30 read with Part A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. The schedule of the meeting is subject to change, which may occur due to exigencies on the part of the investor, analyst, or the company.
Meeting Schedule
| Date | Investor/Analyst/Fund Name | Type of Meeting |
|---|---|---|
| June 25, 2026 | Ambit PMS arranged by B&K / 360One | One-on-One Meetings |
The intimation was signed by Sampath Kumar Pallerlamudi, Company Secretary & Compliance Officer of Gland Pharma Limited.
Historical Stock Returns for Gland Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.10% | +3.85% | -1.53% | +36.20% | +31.75% | -27.80% |
What key topics or strategic updates is Gland Pharma likely to discuss during this meeting?
How might the outcomes of this engagement influence investor sentiment toward Gland Pharma?
Could this meeting signal potential upcoming corporate actions or partnerships for the company?

































